The oxidation and nitration of unsaturated fatty acids transforms cell membrane and lipoprotein constituents into mediators that regulate signal transduction. The formation of 9-NO 2 -octadeca-9,11-dienoic acid and 12-NO 2 -octadeca-9,11-dienoic acid stems from peroxynitrite-and myeloperoxidase-derived nitrogen dioxide reactions as well as secondary to nitrite disproportionation under the acidic conditions of digestion. Broad anti-inflammatory and tissue-protective responses are mediated by nitro-fatty acids. It is now shown that electrophilic fatty acid nitroalkenes are present in the urine of healthy human volunteers (9.9 + 4.0 pmol/mg creatinine); along with electrophilic 16-and 14-carbon nitroalkenyl β-oxidation metabolites. High resolution mass determinations and co-elution with isotopically-labeled metabolites support renal excretion of cysteine-nitroalkene conjugates. These products of Michael addition are in equilibrium with the free nitroalkene pool in urine and are displaced by thiol reaction with HgCl 2 . This reaction increases the level of free nitroalkene fraction >10-fold and displays a K D of 7.5x10 -6 M. In aggregate, the data indicates that formation of Michael adducts by electrophilic fatty acids is favored under biological conditions and that reversal of these addition reactions is critical for detecting both parent nitroalkenes and their metabolites. The measurement of this class of mediators can constitute a sensitive non-invasive index of metabolic and inflammatory status.
INTRODUCTION
Nitro-fatty acid derivatives are formed during both gastric acidification and by the array of oxidative inflammatory reactions that nitric oxide ( . NO) and nitrite (NO 2 -) undergo to induce nitrogen dioxide ( . NO 2 )-dependent biomolecule nitration (1) . Nitroalkene substituents are electrophilic and promote Michael addition of fatty acids with biological nucleophiles such as cysteine and histidine. The extent, rate and reversibility of these reactions will be dictated both by the concentration and reactivity of individual nucleophiles. In this regard, protein structure and compartmentalization affect the reactivity of individual nucleophilic centers and will define the molecular targets of electrophilic fatty acids.
While enzymatically-oxygenated unsaturated fatty acids typically transduce anti-inflammatory actions via specific g protein-coupled receptor (GPCR) ligand activity (2, 3) , transcriptional responses to electrophilic fatty acids reveal that a broader array of signaling events are instigated (4, 5) . The basis for this pleiotropy resides in the facile Michael addition of electrophilic fatty acid derivatives with nucleophilic centers of proteins that regulate structure and function (6) .
Functionally-significant protein targets of electrophilic fatty acids include the transcriptional regulatory protein complex nuclear factor kappa B (NFkB), the Kelch-like ECH-associated protein 1 (Keap1) regulator of nuclear factor (erythroidderived-2)-like 2 (Nrf2), heat shock factor-1 (HSF-1), peroxisome proliferator-activator receptor-γ (PPARγ) and histone deacetylases (HDAC) (7) . These transcriptional regulatory proteins contribute to the control the expression of hundreds of genes that include cytokines, antioxidant enzymes, heat shock response proteins and enzymes of intermediary metabolism (4, 5, (8) (9) (10) (11) (12) (13) (14) .
Conjugated 9,11-linoleic acid appears to be the preferred endogenous substrate for metabolic and inflammatorymediated fatty acid nitration. This is attributed to its clinical abundance and the high reactivity to addition reactions of the external flanking carbons of conjugated dienes, as opposed to monoalkenes or bis-allylic dienes (1) . Once formed, electrophilic nitro fatty acids (NO 2 -FA) can undergo addition to glutathione (GSH), enzymatic reduction to a nonelectrophilic nitroalkene and -oxidation (15, 16) . GSH nitroalkylation products are exported from cells as GSH conjugates by multidrug resistant proteins (MRP) (15) . In turn, GSH-NO 2 -FA conjugates may also be metabolized by peptidases to cysteinylglycine and cysteine conjugates, N-acetylated and excreted via renal or biliary mechanisms.
Herein, we identify the two principal nitro derivatives of conjugated linoleic acid, 9-nitro-octadeca-9,11-dienoic acid and 12-nitro-octadeca-9,11-dienoic acid, in the urine of healthy humans. Electrophilic 16-, 14-and 12-carbon -oxidation metabolites and their corresponding cysteinyl-conjugates were also detected. Structural characterization and quantification via high resolution mass spectrometry was guided by the comparison of endogenous metabolites to both synthetic 9-and 12-15 NO 2 -CLA, and the products of 15 NO 2 -CLA metabolism by isolated and perfused rodent heart. Notably, the detectable Inasmuch as fatty acid nitration is influenced by the dietary, metabolic and inflammatory status of organisms, the present data also provides an approach and perspective for non-invasively detecting the magnitude of redox reactions stemming from metabolism and products of partially reduced oxygen species, . NO and NO 2 -.
EXPERIMENTAL PROCEDURES
Materials -(9Z,11E)-octadeca-9,11-dienoic (9,11-CLA, referred as conjugated linoleic acid, CLA) was purchased from and β-mercaptoethanol (BME) were obtained from Sigma/Aldrich (St Louis, MO). Solvents used for synthetic reactions were of HPLC grade or better from Fisher Scientific (Fairlawn, NJ). Solvents used for extractions and mass spectrometric analyses were from Burdick and Jackson (Muskegon, MI). Solid phase extraction columns (SPE, C-18 reverse phase; 500 mg, 6 ml capacity) were purchased from Thermo Scientific.
Chromatography -Fatty acid nitration products in lipid extracts were analyzed by HPLC-ESI MS/MS using gradient solvent systems consisting of H 2 O containing 0.1% acetic acid (solvent A) and acetonitrile containing 0.1% acetic acid (solvent B). Lipid extracts were resolved for quantitation using a reverse phase HPLC column (2 x 20 mm C18 Mercury column; Phenomenex) at a 0.75 ml/min flow rate. Samples were applied to the column at 11% B (1 min) and eluted with a linear increase in solvent B (11%-100% B in 9 min). Characterization analysis to identify structural isomers and metabolites was performed using an analytical C18 Luna column (2 x 150 mm, 3 µm particle size, Phenomenex) at a 0.25 ml/min flow rate. Samples were resolved using the following gradient program: 0-1 min, 45% solvent B; 1-45 min, from 45 to 80% solvent B; 45-46 min, from 80 to 100% solvent B. BME adduct analysis was performed on an analytical C18 Luna column (2 x 100 mm, 5 µm particle size, Phenomenex) at a 0.75 ml/min flow rate. Samples were resolved using the following gradient program: 0.5-3 min, from 5-35% solvent B; 3-15 min from 35-100% solvent B.
Mass spectrometry -Analytes of interest were characterized both in CID and HCD mode using an LTQ Velos Orbitrap (Velos Orbitrap, ThermoScientific) equipped with a HESI II electrospray source. The following parameters were used:
source temperature 400 ºC, capillary temperature 360 ºC, sheath gas flow 30, auxiliary gas flow 15, sweep gas flow 2, source voltage -3.3 kV, S-lens RF level 44 (%). The instrument FT-mode was calibrated using the manufacturers recommended calibration solution with the addition of malic acid as a low m/z calibration point in the negative ion mode.
Analyte quantification was performed in multiple reaction monitoring mode (MRM) using an AB5000 or a API4000
Qtrap triple quadrupole mass spectrometer (Applied Biosystems; San Jose, CA) equipped with an electrospray ionization source. Internal standard curves using synthetic NO 2 -CLA and 15 NO 2 -CLA were prepared using human urine as matrix to quantify endogenous nitrated fatty acids. Precursor ion scans were performed to identify any other eluting lipids losing a nitro group (m/z 46) upon CID.
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Lipid extraction from urine -Urine samples (first void of the day) were collected from healthy human volunteers Samples were loaded into the SPE column and washed with 2 column volumes of 5% MeOH and the column was dried under vacuum for 30 min. Lipids were eluted with 3 ml MeOH, solvent was evaporated, and samples were dissolved in
MeOH for analysis by HPLC-electrospray ionization mass spectrometry (ESI MS/MS). Nitro-fatty acid levels were normalized to urine creatinine concentrations that were determined using a colorimetric assay measuring absorbance at 535 nm after dilution in NaOH and reaction with picric acid (20) . (Fig 1a-c) (Fig 1d,e) .
Quantification of conjugated diene-containing fatty acid nitration products in human urine. Levels of NO 2 -CLA in human urine were measured in the MRM scan mode using 15 NO 2 -CLA as an internal standard to correct for losses due to extraction. The content of NO 2 -CLA in urine was 9.97 +/-3.98 pmol/mg creatinine, with up to 100-fold differences in basal NO 2 -CLA concentrations in different healthy volunteers (0.5 to 42.6 pmol/mg creatinine, Suppl. Table 1) .
Electrophilic-oxidation products of NO 2 -CLA in urine.
Mitochondrial -oxidation of synthetic NO 2 -OA occurs in mice following intravenous injection (16) . In order to evaluate if endogenous NO 2 -CLA -oxidation metabolites could be detected in human urine, a sequential scan for precursor ions of 46 (NO 2 -) with mass losses of 28 amu (C 2 H 4 ) from the parent NO 2 -CLA was performed. Chromatographic peaks corresponding to dinor-NO 2 -CLA (m/z 296.2, 1 round of -oxidation) and tetranor-NO 2 -CLA (m/z 268.2, 2 rounds of -oxidation) ion precursors were detected (Fig 2a) .
Fatty acid nitration yields electrophilic nitroalkene derivatives that undergo conjugate addition with low and high molecular weight thiols. To test the electrophilic nature of these newly-identified urinary fatty acid nitration products, 500 mM of -mercaptoethanol (BME) was added to urine samples for 2 h and products were determined by LC-MS/MS after extraction (Fig 2) . After BME addition, all species previously identified as nitrated fatty acids were transformed into the corresponding BME addition products and no longer detected at their original retention times (Fig 2b, structures shown in 2d). Peaks co-eluting with BME adducts (Fig. 2b-c ) that displayed the m/z of non-adducted species (Fig. 2c) provided additional diagnostic insight. These peaks reflected in-source fragmentation products due to the neutral loss of BME ( elimination reaction) during adduct ionization (23) . This indicated the electrophilic nitroalkene configuration of both urinary NO 2 -CLA and its -oxidation products, with no other additional hydroxy-, oxo-or non-electrophilic nitroalkanecontaining derivatives of NO 2 -CLA detected in urine (data not shown).
High resolution mass spectrometry comparison of NO 2 -CLA -oxidation products in urine and NO 2 -CLA metabolites
formed by isolated and perfused rat hearts. The addition of nitrated fatty acids to the perfusate of Langendorff rat heart preparations yielded corresponding -oxidation derivatives in the effluent. Thus, 15 NO 2 -CLA was infused into isolated rat hearts in order to generate isotopically-labeled standards for characterizing putative NO 2 -CLA products in human urine.
Accurate mass determinations at the 2 ppm level confirmed the atomic composition of the different NO 2 -CLA metabolites proposed for both human urine and cardiac 15 NO 2 -CLA metabolic products (Fig 3, Table 1 ). This high resolution MS/MS analysis also gave fragmentations that defined these products as 12-NO 2 -hexadeca-9,11-dienoic acid, 9-NO 2 -hexadecaby guest, on October 22, 2017 www.jlr.org Downloaded from 9,11-dienoic acid, (Fig 3a, Suppl Fig 1a) 10-NO 2 -hexadeca-7,9-dienoic acid, 7-NO 2 -hexadeca-7,9-dienoic acid (dinor NO 2 -CLAs) (Fig 3b, Suppl Fig 1b) , 8-NO 2 -hexadeca-5,7-dienoic acid and 5-NO 2 -hexadeca-5,7-dienoic acid (tetranor NO 2 -CLAs) c) (Fig 3c, Suppl Fig 1c) , for both human urine and rodent heart metabolites (See Table 1 for product ion identification). The chromatographic profile of these nitrated fatty acid species correlated between the two sources, supporting the notion that NO 2 -CLA undergoes -oxidation and that these products are present in the urine of healthy humans. Whereas the retention times for the different dinor-NO 2 -CLA isomers were identical, there were differences in the relative ion intensities of particular metabolites generated by cardiac perfusion and present in urine (Fig 3b, peaks 1 and 2). The urine of different subjects presented a strong correlation (R>0.94) between the levels of NO 2 -CLA and its -oxidation products (dinor-and tetranor-NO 2 -CLA) (Fig. 4) , supporting that these 16-and 14-carbon nitroalkenes all shared NO 2 -CLA as the precursor.
Detection and characterization of cysteinyl-nitro-fatty acid conjugates in urine.
Sequential addition to GSH, export to the extracellular space via MRPs and peptidase-mediated cleavage is a potential in vivo route for the metabolic disposition of nitro-fatty acids (15) . Fig 2b) .
The presence of 16 and 14 carbon electrophilic NO 2 -CLA metabolites in urine suggested that these derivatives might also form cysteine conjugates. The presence of Cys-dinor-NO 2 -CLA, Cys-tetranor-NO 2 -CLA and Cys-hexanor-NO 2 -CLA in human urine was evaluated by MS/MS in the negative and positive ion mode. In the negative ion mode, the fragmentation of these addition products is characterized by neutral losses of the nitrated fatty acid and cysteine moiety, albeit the latter is less prevalent. Selective reaction monitoring of the neutral loss of the nitroalkene precursor led to the detection of addition products containing 16, 14 and 12 carbon long nitro-fatty acids (Suppl Fig 2b) . In order to confirm the identity of these metabolites, cysteine-conjugated standards were prepared from 15 NO 2 -CLA -oxidation metabolites obtained from isolated and perfused rat hearts. The retention times and peak patterns obtained from heart-derived metabolites closely matched those obtained from urine samples (Fig 5a) . The peak multiplicity observed both in rodent heart and human urine samples likely results from the different isomeric configurations that nitroalkenes can adopt upon successive cycles of cysteine addition and release. Finally, the atomic composition of all metabolites was confirmed by high resolution mass analysis (Suppl Fig 2c) . Importantly, fragmentation analysis of cysteine adducts yielded the canonical neutral loss of HNO 2 , a hallmark for nitro-containing fatty acids including nitroalkylated peptides, bisallylic and monounsaturated nitroalkenes and NO 2 -CLA (Fig 5b inset) (14, 17, 24) .
The presence of mercapturate-NO 2 -CLA conjugates in human urine was evaluated by producing a synthetic standard from the reaction of N-acetyl-cysteine with 15 NO 2 -CLA. Mass spectrometric analysis indicated that these compounds fragment in the negative ion mode with neutral losses of the conjugated fatty acid. Single reaction monitoring of urine revealed that these species were detectable at trace levels not warranting or allowing further characterization. (Fig 6a-b) . Expanding on this insight, human urine was treated with the thiol-reactive Lewis acid HgCl 2 . The reaction of HgCl 2 (10 mM) for 30 min at 37 °C promoted the release of free nitroalkenes, concomitant with the complete loss of the cysteine-conjugates. Similar results were obtained with different chain length nitro-fatty acid metabolites (Fig 7) .
Equilibrium constant of the NO 2 -FA reaction with cysteine. To better define the reversibility of thiol addition to reactive nitroalkenes, the equilibrium constant for the reaction between cysteine and NO 2 -OA was determined. Nitro-oleic acid is a prototypic nitroalkene for which reaction rates with GSH have been characterized (25) . The formation of Cys-NO 2 -OA was monitored by UV-visible spectroscopy and analyzed by non-linear deconvolution (Fig 8a) . NO 2 -OA was incubated with increasing concentrations of cysteine thiolate and the relative concentrations of free and adducted nitroalkene were determined by spectral deconvolution (Fig 8b) . Finally, a dissociation constant (K D = 7.5 x 10 -6 M) was derived by fitting fractional lipid binding values obtained at increasing concentration of added thiolate to a one-site hyperbolic binding model (Fig 8c) . The presence of NO 2 -CLA and its derivatives in human urine samples was confirmed by comparison with corresponding 15 N-labeled standards, as well as by high resolution MS analysis. While the levels of NO 2 -CLA, dinor-NO 2 -CLA and tetranor-NO 2 -CLA were similar in human urine (Fig 4) , the concentration of hexanor-NO 2 -CLA was considerably lower.
This contrasts with the metabolite profile obtained from NO 2 -CLA-perfused rat hearts, where the levels of dinor-NO 2 -CLA were lower than those of NO 2 -CLA and tetranor-NO 2 -CLA. This indicates either species-specific differences in metabolism or an intrinsic inability of dinor-NO 2 -CLA to escape the -oxidation cycle in heart tissue. Thus, the endogenous formation of dinor-NO 2 -CLA most likely stems from non-cardiac tissues. Moreover, the isomeric composition of dinor-NO 2 -CLA from rat heart is different from that observed in human urine. The multiplicity of peaks detected in cardiac venous outflow may be a result of conjugated diene stereoisomerization after Michael addition to, and then release from, nucleophilic targets.
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The Michael addition of nitroalkenes to GSH has been reported in plasma, tissues and cells in culture (24) . These products are preferentially formed intracellularly via non-enzymatic conjugation in a compartment where GSH concentrations are ~6 mM, (15, 35) . In this regard, glutathione-S-transferases (GSTA1-1, A4-4, M1a-1a, and P1a-1a) do not participate in GSH conjugation of nitrated linoleic and oleic acid (35). Inactive GSH conjugates are then exported to the extracellular milieu through MRPs to enter the circulation (15) and processed by hepatic -glutamyl transpeptidases and renal dipeptidases to yield cysteine conjugates analogous to those of leukotriene metabolism (36-38). Thus, a comprehensive detection of electrophilic lipid metabolites in the urine also encompasses cysteine and mercapturate conjugates, as for isothiocyanates (39) . Human urine revealed higher levels of nitroalkene-cysteine conjugates, compared with free fatty acid or mercapturic acid derivatives. Although mercapturates are typically in greater concentrations than cysteine conjugates in urine, this observation is not uncommon, as leukotriene E4 levels are 9-fold greater than those of its Nacetyl derivatives (40) . The present data reveal that upon nitroalkene generation, a chemical equilibrium between free and Cys-adducted nitro fatty acids is promptly established. Depending on the relative on/off rates for nitroalkene addition to GSH and protein targets, as well as the rate of MRP-mediated export of GSH conjugates; plasma, urine and tissue levels of free nitroalkenes can be efficiently regulated. This dynamic system provides a mechanism for the modulation of nitroalkene signaling in response to changes in tissue inflammatory status. Overall, these observations support that the formation and signaling actions of electrophilic nitroalkenes constitutes a physiological mechanism that is manifested in humans under healthy conditions.
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